Mutations Explain Late Progression in Pembrolizumab-Treated Melanoma

Researchers have identified several genetic mutations in metastatic melanoma that are behind acquired resistance to programmed death 1 therapy.

Source: MedWire News - July 19, 2016 Category: Consumer Health News Tags: Melanoma Source Type: news